They are just engrossed with Remplir US expansion is all, per this update. The asset is there and the ATI/ACI science is making money, just elsewhere alas. Vericel has for example made (USD) $165 million in 2023, $197 millioin in 2024 and 2025 net revenue expected to be approximately $240 million.
Still served financial purpose, as without the seed money from ACI, Orthocell and Striate (with its partnership with HenrySchein/BioHorizons) and Remplir, etc, etc, would not be of course....
They are just engrossed with Remplir US expansion is all, per...
Add to My Watchlist
What is My Watchlist?